Sandesh Mahatme's Insider Trades & SAST Disclosures

Sandesh Mahatme's most recent trade in CRISPR Therapeutics AG was a trade of 13,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 30, 2024.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
CRISPR Therapeutics AG
Sandesh Mahatme Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 May 2024 13,000 13,000 - - Stock Option (Right to Buy)
Aeglea BioTherapeutics Inc
Sandesh Mahatme Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jun 2022 43,000 43,000 - - Director Stock Option (right to buy)
Aeglea BioTherapeutics Inc
Sandesh Mahatme Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Jun 2021 40,000 40,000 - - Director Stock Option (right to buy)
Aeglea BioTherapeutics Inc
Sandesh Mahatme Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 08 Jun 2020 28,100 28,100 - - Director Stock Option (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades